<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-513</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АНАЛИТИЧЕСКИЕ МЕТОДИКИ И МЕТОДЫ КОНТРОЛЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ANALYTICAL AND QUALITY CONTROL METHODS</subject></subj-group></article-categories><title-group><article-title>КОЛИЧЕСТВЕННОЕ ОПРЕДЕЛЕНИЕ СОДЕРЖАНИЯ БЕЛКОВ КЛЕТОК ХОЗЯИНА (СHO) МЕТОДОМ ИММУНОФЕРМЕНТНОГО АНАЛИЗА В БЕЛКЕ АДАЛИМУМАБ</article-title><trans-title-group xml:lang="en"><trans-title>QUANTITATIVE DETERMINATION OF HOST CELL PROTEINS (CHO) BY THE METHOD OF ENZYME IMMUNOASSAY IN THE PROTEIN ADALIMUMAB</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исайкина</surname><given-names>П. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Isaykina</surname><given-names>P. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгова</surname><given-names>В. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgova</surname><given-names>V. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аскретков</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ascretcov</surname><given-names>A. D.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орлова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Orlova</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Московский технологический университет» (Институт тонких химических технологий)<country>Россия</country></aff><aff xml:lang="en">Moscow Technological University (Institute of fine chemical technologies)<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБУ «Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов» («ГосНИИгенетика»)<country>Россия</country></aff><aff xml:lang="en">Scientific Center of Russian Federation Research Institute for Genetics and Selection of Industrial Microorganisms<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>4</issue><fpage>166</fpage><lpage>175</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Исайкина П.М., Долгова В.П., Аскретков А.Д., Орлова Н.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Исайкина П.М., Долгова В.П., Аскретков А.Д., Орлова Н.В.</copyright-holder><copyright-holder xml:lang="en">Isaykina P.M., Dolgova V.P., Ascretcov A.D., Orlova N.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/513">https://www.pharmjournal.ru/jour/article/view/513</self-uri><abstract><p>Наличие белков к леток хозяина (HCP) из CHO-клеток в конечном продукте чревато рядом негативных последствий, в связи с этим для получения продукта над лежащего качества необходимо обеспечивать тщательную очистку целевых белков от HCP. Таким образом, при разработке технологии получения готового белкового продукта стоит задача по снижению загрязнения HCP до минимальных уровней. Проведено сравнение наборов иммуноферментного анализа 2-го и 3-го поколения Cygnus technologies для количественной оценки белков клеток хозяина (СHO) в субстанции моноклонального антитела - адалимумаб. В ходе исследования было выяснено, что набор 2-го поколения не показывает истинный уровень белков к леток хозяина, занижая результат. В связи с этим возникает необходимость подтвердить валидность метода определения содержания белков к леток хозяина (СНО) набором 3-го поколения в субстанции адалимумаба по следующим аналитическим характеристикам: тест пригодности системы, специфичность, предел обнаружения, нижний предел измерения, верхний предел измерения, правильность, повторяемость, воспроизводимость, надежность.</p></abstract><trans-abstract xml:lang="en"><p>Is necessary to ensure thorough purification of the target proteins, since the presence of host cell proteins (HCP) from CHO cells in the final product is fraught with a number of negative consequences. Thus, it is has to reduce the contamination of HCP to minimum levels. A comparison of the immunoenzymatic assays of the second and third generations of Cygnus technologies for the quantification of host cell proteins (CHO) in a monoclonal antibody adalimumab was done. It was found that a kit of the 2nd generation does not show the true level of the host cell proteins, underestimating the result. In this connection, it becomes necessary to confirm the validity of the method for determining the total quantity of host cell proteins (CHO) by a set of 3rd generation in adalimumab substance according to the following analytical characteristics: system suitability test, specificity, limit of detection, limit of quantitation, hook capacity, precision.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>адалимумаб</kwd><kwd>моноклональные антитела</kwd><kwd>иммуноферментный анализ (ELISA)</kwd><kwd>белки клеток хозяина (CHO)</kwd><kwd>валидация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>adalimumab</kwd><kwd>monoclonal antibodies</kwd><kwd>enzyme immunoassay</kwd><kwd>host cell proteins (CHO)</kwd><kwd>ELISA</kwd><kwd>validation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">D. Ternant, E. Ducourau, P. Fuzibet et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br. // J. Clin. Pharmacol. 2015. № 79(2). Р. 286-297.</mixed-citation><mixed-citation xml:lang="en">D. Ternant, E. Ducourau, P. Fuzibet et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br. // J. Clin. Pharmacol. 2015. № 79(2). Р. 286-297.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">V.N. Sisodiya, J. Lequieu, M. Rodriguez et al. Studying host cell protein interactions with monoclonal antibodies using high throughput protein A chromatography // Biotechnology Journal. 2012. № 7(10). Р. 1233-1241.</mixed-citation><mixed-citation xml:lang="en">V.N. Sisodiya, J. Lequieu, M. Rodriguez et al. Studying host cell protein interactions with monoclonal antibodies using high throughput protein A chromatography // Biotechnology Journal. 2012. № 7(10). Р. 1233-1241.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">D. Ren, M.R. Darlucio, J.H. Chou. Development of a multi-product leached protein A assay for bioprocess samples containing recombinant human monoclonal antibodies // Journal of Immunological Methods. 2011. V. 366. Р. 20-27.</mixed-citation><mixed-citation xml:lang="en">D. Ren, M.R. Darlucio, J.H. Chou. Development of a multi-product leached protein A assay for bioprocess samples containing recombinant human monoclonal antibodies // Journal of Immunological Methods. 2011. V. 366. Р. 20-27.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">S.X. Gao, Y. Zhang, K. Stansberry-Perkins et al. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity // Biotechnol Bioeng. 2011. № 108(4). Р. 977-982.</mixed-citation><mixed-citation xml:lang="en">S.X. Gao, Y. Zhang, K. Stansberry-Perkins et al. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity // Biotechnol Bioeng. 2011. № 108(4). Р. 977-982.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Partnership for Public Service. The state of the FDA workforce. - Washington, DC: Author, retrieved, 2017.</mixed-citation><mixed-citation xml:lang="en">Partnership for Public Service. The state of the FDA workforce. - Washington, DC: Author, retrieved, 2017.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Y.H. Kao, D.P. Hewitt, M. Trexler-Schmidt et al. Mechanism of antibody reduction in cell culture production processes // Biotechnol Bioeng. 2010. № 107(4). Р. 622-632.</mixed-citation><mixed-citation xml:lang="en">Y.H. Kao, D.P. Hewitt, M. Trexler-Schmidt et al. Mechanism of antibody reduction in cell culture production processes // Biotechnol Bioeng. 2010. № 107(4). Р. 622-632.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">M. Trexler-Schmidt, S. Sargis, J. Chiu. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing // Biotechnol Bioeng. 2010. № 106(3). Р. 452-461.</mixed-citation><mixed-citation xml:lang="en">M. Trexler-Schmidt, S. Sargis, J. Chiu. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing // Biotechnol Bioeng. 2010. № 106(3). Р. 452-461.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">K. Champion, H. Madden, J. Dougherty et al. Defining your product profile and maintaining control over it, part 2 // BioProcess Int. 2005. № 3(8). Р. 52-57.</mixed-citation><mixed-citation xml:lang="en">K. Champion, H. Madden, J. Dougherty et al. Defining your product profile and maintaining control over it, part 2 // BioProcess Int. 2005. № 3(8). Р. 52-57.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">D.P. Speicher. Current protocols in protein science, Chapter 10, Section II. Electrophoretic separation of proteins. - Hoboken, NJ: John Wiley and Sons, 2008. Р. 10.2.1-10.5.1.</mixed-citation><mixed-citation xml:lang="en">D.P. Speicher. Current protocols in protein science, Chapter 10, Section II. Electrophoretic separation of proteins. - Hoboken, NJ: John Wiley and Sons, 2008. Р. 10.2.1-10.5.1.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">X. Wang, A.K. Hunter, N.M. Mozier. Host Cell Proteins in Biologics Development: Identification, Quantitation and Risk Assessment // Biotechnology and Bioengineering. 2015. № 103(3). Р. 446-458.</mixed-citation><mixed-citation xml:lang="en">X. Wang, A.K. Hunter, N.M. Mozier. Host Cell Proteins in Biologics Development: Identification, Quantitation and Risk Assessment // Biotechnology and Bioengineering. 2015. № 103(3). Р. 446-458.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">N. Kochanowsk, G. Siriez, L. Mukankurayija et al. Host cell protein platform assay development for therapeutic mAb bioprocessing using mammalian cells // BioMed Central. 2015. № 9(9). Р. 21.</mixed-citation><mixed-citation xml:lang="en">N. Kochanowsk, G. Siriez, L. Mukankurayija et al. Host cell protein platform assay development for therapeutic mAb bioprocessing using mammalian cells // BioMed Central. 2015. № 9(9). Р. 21.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">J. Zhu-Shimoni, C. Yu, J. Nishihara, R.M. Wong et al. Host cell protein testing by ELISAs and the use of orthogonal methods // Biotechnol. Bioeng. 2014. № 111(12). Р. 2367-2379.</mixed-citation><mixed-citation xml:lang="en">J. Zhu-Shimoni, C. Yu, J. Nishihara, R.M. Wong et al. Host cell protein testing by ELISAs and the use of orthogonal methods // Biotechnol. Bioeng. 2014. № 111(12). Р. 2367-2379.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Э.Э. Досадина, М.А. Кульметьева, О.Э. Дубовикова и т.д. Синтез и исследование свойств комплекса протеиназ, иммобилизованных на полисахаридных носителях, для медицинского использования // Бутлеровские сообщения. 2016. Т. 46. № 6. С. 1-10.</mixed-citation><mixed-citation xml:lang="en">Э.Э. Досадина, М.А. Кульметьева, О.Э. Дубовикова и т.д. Синтез и исследование свойств комплекса протеиназ, иммобилизованных на полисахаридных носителях, для медицинского использования // Бутлеровские сообщения. 2016. Т. 46. № 6. С. 1-10.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">А.Н. Агафонова, Ю.А. Лейкин. Получение и обнаружение антител различных модификаций // Бутлеровские сообщения. 2016. Т. 46. № 6. С. 24-27.</mixed-citation><mixed-citation xml:lang="en">А.Н. Агафонова, Ю.А. Лейкин. Получение и обнаружение антител различных модификаций // Бутлеровские сообщения. 2016. Т. 46. № 6. С. 24-27.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">D. Ahluwalia, Н. Dhillon, Т. Slaney. Identification of a host cell protein impurity in therapeutic protein // Journal of Pharmaceutical and Biomedical Analysis. 2017. V. 141. Р. 32-38.</mixed-citation><mixed-citation xml:lang="en">D. Ahluwalia, Н. Dhillon, Т. Slaney. Identification of a host cell protein impurity in therapeutic protein // Journal of Pharmaceutical and Biomedical Analysis. 2017. V. 141. Р. 32-38.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cygnus Technologies. URL: https://cygnustechnologies.com (дата обращения 10.09.2017).</mixed-citation><mixed-citation xml:lang="en">Cygnus Technologies. URL: https://cygnustechnologies.com (дата обращения 10.09.2017).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">ОФС.1.1.0012.15. Валидация аналитических методик // Государственная Фармакопея РФ XIII изд. Т. 1. - М. 2015.</mixed-citation><mixed-citation xml:lang="en">ОФС.1.1.0012.15. Валидация аналитических методик // Государственная Фармакопея РФ XIII изд. Т. 1. - М. 2015.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
